Biofrontera Inc (NASDAQ:BFRI) — Market Cap & Net Worth
Market Cap & Net Worth: Biofrontera Inc (BFRI)
Biofrontera Inc (NASDAQ:BFRI) has a market capitalization of $14.47 Million ($14.47 Million) as of August 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #26054 globally and #5383 in its home market, demonstrating a 7.34% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Biofrontera Inc's stock price $1.17 by its total outstanding shares 12803344 (12.80 Million). See Biofrontera Inc (BFRI) capital reinvestment to understand how much of operating cash flow is reinvested back into capital assets.
Biofrontera Inc Market Cap History: 2021 to 2026
Biofrontera Inc's market capitalization history from 2021 to 2026. Data shows change from $1.93 Billion to $14.98 Million (-59.70% CAGR).
Index Memberships
Biofrontera Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.00% | #732 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.00% | #2408 of 3165 |
Weight: Biofrontera Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Biofrontera Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Biofrontera Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.17x
Biofrontera Inc's market cap is 0.17 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.93 Billion | $24.10 Million | -$37.71 Million | 79.90x | N/A |
| 2022 | $234.81 Million | $28.67 Million | -$640.00K | 8.19x | N/A |
| 2023 | $35.47 Million | $34.07 Million | -$20.13 Million | 1.04x | N/A |
| 2024 | $13.96 Million | $37.30 Million | -$17.76 Million | 0.37x | N/A |
| 2025 | $7.30 Million | $41.70 Million | -$10.54 Million | 0.17x | N/A |
Competitor Companies of BFRI by Market Capitalization
Companies near Biofrontera Inc in the global market cap rankings as of August 3, 2026.
Key companies related to Biofrontera Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #503 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #528 globally with a market cap of $50.48 Billion USD ( CN¥344.98 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #550 globally with a market cap of $48.78 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #503 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #528 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.48 Billion | CN¥54.08 |
| #550 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.60 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €14.80 |
Biofrontera Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Biofrontera Inc's market cap moved from $1.93 Billion to $ 14.98 Million, with a yearly change of -59.70%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $14.98 Million | +105.26% |
| 2025 | $7.30 Million | -47.71% |
| 2024 | $13.96 Million | -60.65% |
| 2023 | $35.47 Million | -84.90% |
| 2022 | $234.81 Million | -87.81% |
| 2021 | $1.93 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 3rd, 2026 the market cap of Biofrontera Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $14.47 Million USD |
| MoneyControl | $14.47 Million USD |
| MarketWatch | $14.47 Million USD |
| marketcap.company | $14.47 Million USD |
| Reuters | $14.47 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Biofrontera Inc
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquarte… Read more